Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal
system and stimulate the immune system. Necrotizing enterocolitis incidence is 10-25% in
newborn infants whose birth weights are < 1500 g. Although bifidobacterium and other
lactobacilli spp. have been used to reduce the incidence of necrotizing enterocolitis in
clinical trials, Lactobacillus reuteri has not been used in the prevention of necrotizing
enterocolitis in very low birth weight infants yet. The objective of this study is to
evaluate the efficacy of orally administered Lactobacillus reuteri in reducing the incidence
and severity of necrotizing enterocolitis in very low birth weight infants.
Phase:
Phase 3
Details
Lead Sponsor:
Zekai Tahir Burak Women's Health Research and Education Hospital